-
Je něco špatně v tomto záznamu ?
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications
P. Vlček, J. Polák, M. Brunovský, J. Horáček,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
NV15-29370A
MZ0
CEP - Centrální evidence projektů
NV15-34524A
MZ0
CEP - Centrální evidence projektů
PubMed
28950396
DOI
10.1055/s-0043-118665
Knihovny.cz E-zdroje
- MeSH
- glutamátové receptory metabolismus MeSH
- kognitivní poruchy etiologie MeSH
- kyselina glutamová metabolismus MeSH
- látky působící na systém excitačních aminokyselin terapeutické užití MeSH
- lidé MeSH
- mozek účinky léků metabolismus MeSH
- neuropsychologické testy MeSH
- obsedantně kompulzivní porucha komplikace farmakoterapie metabolismus patologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Although its pathogenesis remains unclear, the traditional model focused on alternations in the serotonin system. Selective serotonin reuptake inhibitors provide the most effective treatment; however, as much as 40-60% of patients do not respond to antidepressants therapy. Thus, attention has shifted towards other neurotransmitter systems and related neuroanatomical structures. Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis. In this review, we link together the existent neuroanatomical, neurophysiological, and neuropsychological evidence to argue for potential benefits of adjuvant treatment with glutamatergic agents, especially memantine. By a targeted de-excitation effect on the glutamatergic system in the temporal lobes and connected brain regions, memantine might further alleviate OCD symptoms. This effect should be even more pronounced in certain subtypes of patients with specific cognitive deficits and maladaptive compensatory memory processes (e.g., checkers).
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001171
- 003
- CZ-PrNML
- 005
- 20201116114529.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1055/s-0043-118665 $2 doi
- 035 __
- $a (PubMed)28950396
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Vlček, Přemysl, $d 1978- $7 xx0233915 $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
- 245 10
- $a Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications / $c P. Vlček, J. Polák, M. Brunovský, J. Horáček,
- 520 9_
- $a Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. Although its pathogenesis remains unclear, the traditional model focused on alternations in the serotonin system. Selective serotonin reuptake inhibitors provide the most effective treatment; however, as much as 40-60% of patients do not respond to antidepressants therapy. Thus, attention has shifted towards other neurotransmitter systems and related neuroanatomical structures. Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis. In this review, we link together the existent neuroanatomical, neurophysiological, and neuropsychological evidence to argue for potential benefits of adjuvant treatment with glutamatergic agents, especially memantine. By a targeted de-excitation effect on the glutamatergic system in the temporal lobes and connected brain regions, memantine might further alleviate OCD symptoms. This effect should be even more pronounced in certain subtypes of patients with specific cognitive deficits and maladaptive compensatory memory processes (e.g., checkers).
- 650 _2
- $a mozek $x účinky léků $x metabolismus $7 D001921
- 650 _2
- $a kognitivní poruchy $x etiologie $7 D003072
- 650 _2
- $a látky působící na systém excitačních aminokyselin $x terapeutické užití $7 D018683
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a kyselina glutamová $x metabolismus $7 D018698
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a neuropsychologické testy $7 D009483
- 650 _2
- $a obsedantně kompulzivní porucha $x komplikace $x farmakoterapie $x metabolismus $x patologie $7 D009771
- 650 _2
- $a glutamátové receptory $x metabolismus $7 D017470
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Polák, Jakub, $d 1982- $7 jo2007251135 $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic.
- 700 1_
- $a Brunovský, Martin $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
- 700 1_
- $a Horáček, Jiří $u National Institute of Mental Health, Topolová 748, 250 67 Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic.
- 773 0_
- $w MED00003796 $t Pharmacopsychiatry $x 1439-0795 $g Roč. 51, č. 6 (2018), s. 229-242
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28950396 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20201116114529 $b ABA008
- 999 __
- $a ok $b bmc $g 1365078 $s 1039294
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 51 $c 6 $d 229-242 $e 20170926 $i 1439-0795 $m Pharmacopsychiatry $n Pharmacopsychiatry $x MED00003796
- GRA __
- $a NV15-29370A $p MZ0
- GRA __
- $a NV15-34524A $p MZ0
- LZP __
- $a Pubmed-20190107